Marshall Wace North America L.P. 13D and 13G filings for Acrivon Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 09:51 am Sale | 2023-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV | Marshall Wace North America L.P. | 597,469 2.700% | -625,783 (-51.16%) | Filing |
| 2023-02-14 09:35 am Purchase | 2022-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV | Marshall Wace North America L.P. | 1,223,252 5.900% | 1,223,252 (New Position) | Filing |